Description

PharmaQo Drostanolone E 200 is a pharmaceutical-grade injectable delivering 200 mg/mL Drostanolone Enanthate, studied in research settings for androgen receptor binding, anti-catabolic effects, and investigational use in estrogen-sensitive condition models.

The enanthate ester offers a longer half-life compared to propionate, allowing for less frequent dosing in long-term research protocols.

Product Details:
Active Ingredient:

• Drostanolone Enanthate

Concentration: 200 mg/mL

Form: Injectable solution (intramuscular)

Vial Size: 10 mL multidose vial

Pharmacokinetics:
Drostanolone Enanthate has an approximate half-life of 5–7 days, supporting weekly or twice-weekly administration in investigational studies.

Usage Recommendations:

• Indications (Research Context): Investigational use in androgenic and anti-catabolic research, estrogen-related condition studies (not approved for human use)

• Typical Dosage (Research Use): 400–600 mg per week, depending on study design

• Monitoring: Lipid profile, androgenic markers, cardiovascular parameters, liver function

• Cycle/Duration: 8–12 weeks per research protocol

Disclaimer:
This product is intended strictly for research and educational purposes. It is not for human consumption or therapeutic use. Not suitable for individuals under 18, pregnant or breastfeeding women, or those with medical risks. Always comply with local research laws and ethical standards.